Effectiveness of COVID-19 treatment with nirmatrelvir–ritonavir or molnupiravir among US...

Treatment Experience With Oral Antivirals for US Veterans With COVID-19 Infection

A Njoroge, M Froehlich, G Psevdos - Infectious Diseases in …, 2023 - journals.lww.com
COVID-19; however, the fact that vaccinated individuals could still get infected necessitated
the need for effective antiviral therapy. Whereas remdesivir can only be given intravenously …
相关文章 所有 2 个版本
[PDF] researchgate.net

[PDF][PDF] Nirmatrelvir-Ritonavir for the Treatment of COVID-19

N Eze, B Asante, C Spry, F Clement - 2023 - researchgate.net
The findings suggest nirmatrelvir-ritonavir reduces the risk of disease progression,
hospitalization, or death compared to placebo or standard of care in people with mild to …
相关文章 所有 2 个版本
[PDF] udc.es

COVID-19 crítico, análisis del impacto clínico y en la organización de las Unidades de Cuidados Intensivos

P Vidal-Cortés - 2023 - ruc.udc.es
El SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) ha provocado mas de
767 millones de infecciones y cerca de 7 millones de muertes y ha desestabilizado incluso …
相关文章 所有 5 个版本

Molnupiravir Treatment for COVID-19 in People at Higher Risk in the Community: Outcomes from the PANORAMIC Randomised Controlled Trial at Three and Six …

V Harris, J Holmes, O Gbinigie, NM Rahman… - papers.ssrn.com
Objectives: Treating COVID-19 infection with antiviral drugs may reduce the longer-term
impact of the illness, but no randomised controlled trials have yet reported on the …
相关文章

Current Perspective of the Drug-Drug Interaction between Inhaled Medicines and Nirmatrelvir/Ritonavir

RA Pleasants, RM Swier - papers.ssrn.com
The ramifications of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are
unprecedented. Early in the pandemic, individuals with obstructive lung diseases were …
相关文章